Skip to Main Content

Paper Details

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups.
J Immunother Cancer
10
2021
Author NameAffiliation
Chul AhnUniversity of Texas Southwestern Medical Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
  • 1 - 2

Datasets

Release 1.2